Recent remarkable advances in molecular targeted therapies for advanced NSCLC harboring mutations such as ALK and ROS1 rearrangement have extended the survival of these patients.3–6,20 However, safety concerns such as ocular toxicities with crizotinib.12,16 and neurotoxicity with entrectinib.17 have emerged, highlighting the need for the development of effective and safer molecular targeted therapeutic agents. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.